Biocon Biologics India Limited is India’s largest and fully-integrated, innovation-led biopharmaceutical company. As an emerging global biopharmaceutical enterprise, it is committed to reduce therapy costs of chronic diseases like autoimmune, diabetes and cancer. Through innovative products and research services it is enabling access to affordable healthcare for patients, partners and healthcare systems across the globe. Biocon’s key innovations include an indigenous recombinant human insulin based on proprietary fermentation technology, Insugen®; insulin analog Glargine, Basalog®; India’s first indigenously produced monoclonal antibody, BIOMAb-EGFR®; the world’s first humanized anti-CD6 monoclonal antibody, Itolizumab, launched as ALZUMAb™ in India; CANMAb™, the first follow-on biologic Trastuzumab to be approved anywhere in the world.